Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413853 | 0.86 | ALDH1A1 (0.36) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL18418890 | 0.83 | GAA (0.36) | ALDH1A1POLBKMT2ACYP2C19KDM5B | |
| SCHEMBL29339901 | 0.83 | KDM5B (0.33) | CYP2C19KDM5BABL1CD274GAA | |
| SCHEMBL31413839 | 0.82 | ALDH1A1 (0.34) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL14903851 | 0.81 | KMT2A (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL1476343 | 0.80 | KDM5B (0.33) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL31413798 | 0.80 | ALDH1A1 (0.33) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL30376074 | 0.78 | KDM5B (0.36) | ALDH1A1POLBKMT2ACYP2C19KDM5B | |
| SCHEMBL25189871 | 0.78 | ALDH1A1 (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 | |
| SCHEMBL38651558 | 0.78 | ALDH1A1 (0.38) | ALDH1A1POLBKMT2ASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | disclosed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | disclosed |
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-25 | — | — | US | disclosed |
| CN-113272297-B | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| CN-113272297-A | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020079457-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| EP-2029602-B1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-04-21 | — | — | EP | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| US-7501411-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-2029602-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-04-17 | — | — | US | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138072-A2 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234227-B2 | Pyrazole derivatives as H4 antagonist compounds | HRH4, HRH3, HRH2 | ALDH1A1 973/4885POLB 4495/4885KMT2A 1369/4885 |
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | ALDH1A1 1020/4885POLB 2389/4885KMT2A 4428/4885 |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | ALDH1A1 1095/4885POLB 4378/4885KMT2A 1080/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | ALDH1A1 1095/4885POLB 4378/4885KMT2A 1080/4885 |
| US-20080090818-A1 | Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases | P2RX5, P2RX3, IL1B | ALDH1A1 698/4885POLB 1559/4885KMT2A 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.